Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen
This article was originally published in The Pink Sheet Daily
Executive Summary
There is no evidence to suggest Crestor (rosuvastatin) should be withdrawn because of its renal or muscle toxicity profiles, FDA says in its rejection of Public Citizen's petition. "For any degree of LDL-lowering, rosuvastatin is as safe, and may well be safer than, any other marketed statin with regard to muscle toxicity," FDA says.
You may also be interested in...
Statin Safety Report Due Out At Year-End, National Lipid Assoc. Says
Preliminary results of the National Lipid Association statin safety task force's retrospective study of claims database shows Crestor's incidence of renal events and rhabdomyolysis fall in the middle of the statin class.
Statin Safety Report Due Out At Year-End, National Lipid Assoc. Says
Preliminary results of the National Lipid Association statin safety task force's retrospective study of claims database shows Crestor's incidence of renal events and rhabdomyolysis fall in the middle of the statin class.
Abbott Says Decision To Discontinue Cylert Stems From Demand, Not Safety
Significant decline in pemoline sales is reason behind the ADHD agent's discontinuation, not liver safety issues raised in a Public Citizen petition to FDA, Abbott says. Public Citizen seeks withdrawal of Cylert and generics; the petition references two analyses of pemoline conducted by FDA drug safety officer Graham.